학술논문
1451MO In-situ immune markers predict nivolumab (N) +/-ipilimumab (I) efficacy in frontline metastatic clear cell renal cell carcinoma (mccRCC): Key ancillary analyses from the BIONIKK randomized trial
Document Type
Abstract
Author
Source
In Annals of Oncology September 2022 33 Supplement 7:S1207-S1207
Subject
Language
ISSN
0923-7534